413 related articles for article (PubMed ID: 34572593)
1. Stress-Induced Epstein-Barr Virus Reactivation.
Sausen DG; Bhutta MS; Gallo ES; Dahari H; Borenstein R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572593
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR
J Clin Pathol; 2019 Oct; 72(10):651-658. PubMed ID: 31315893
[TBL] [Abstract][Full Text] [Related]
3. Autonomic and glucocorticoid associations with the steady-state expression of latent Epstein-Barr virus.
Cacioppo JT; Kiecolt-Glaser JK; Malarkey WB; Laskowski BF; Rozlog LA; Poehlmann KM; Burleson MH; Glaser R
Horm Behav; 2002 Aug; 42(1):32-41. PubMed ID: 12191645
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
5. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
6. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
7. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
8. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
9. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.
Bentz GL; Lowrey AJ; Horne DC; Nguyen V; Satterfield AR; Ross TD; Harrod AE; Uchakina ON; McKallip RJ
PLoS One; 2019; 14(5):e0217578. PubMed ID: 31125383
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
12. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infections: prospects for treatment.
Gershburg E; Pagano JS
J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
16. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
18. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapeutics for Epstein⁻Barr Virus.
Andrei G; Trompet E; Snoeck R
Molecules; 2019 Mar; 24(5):. PubMed ID: 30871092
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.
Petrara MR; Giunco S; Serraino D; Dolcetti R; De Rossi A
Cancer Lett; 2015 Dec; 369(1):37-44. PubMed ID: 26279520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]